The discovery that FSHD pathogenesis is caused by misexpression of DUX4 has spurred the identification of numerous potential therapeutic targets, both upstream and downstream of the pathogenic gene. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.